The last 7. years have seen the treatment landscape for metastatic renal cell carcinoma (mRCC) dramatically change as the understanding of the molecular background of the disease has grown. With the increase in treatment options, however, comes the question of how best to maximise patient benefits based on the available medicines. This topic was the key focus of a Pfizer meeting held at the 8th European International Kidney Cancer Symposium (EIKCS) in Budapest, Hungary (3-4 May 2013), where leading oncology experts reviewed the latest clinical trial evidence and discussed the importance of real world experience in treating patients with mRCC. This report offers an overview of the discussion on how best to integrate clinical trial data, guideline recommendations and real world experience in order to make treatment decisions that will provide the maximum benefit for each individual patient.
- Metastatic renal cell carcinoma
ASJC Scopus subject areas
- Cancer Research